Co-authored by investigators of VHIO’s Cancer Genomics Group and Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, results…
Elena Garralda
In her latest On target column published by the ESMO Daily Reporter, VHIO’s Elena Garralda discusses the expanding toolbox for immuno-oncology in advanced…
For many cancer patients, clinical trials are a new opportunity for treatment, especially in cases where various therapies have been…
Advances driven by research have led to significant developments in better understanding the molecular taxonomy of cancer and therapeutic breakthroughs…
Published by ESMO’s Daily Reporter, Elena Garralda’s latest On target column explores the promise of neoadjuvant immunotherapy in the treatment…
The ultrasensitive liquid biopsy technique applied in this work is based on the sequencing of the entire tumour genome from…
Initial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that it is a drug with…
The predictability of response criteria remains controversial in drug development. Numerous reviews and meta-analyses continue to question the reliability of…
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
In her latest On target column, published by ESMO’s Daily Reporter, VHIO’s Elena Garralda reflects on the myriad research advances presented at last month’s…
